Burning Rock Biotech (BNR) AI Stock Analysis

• Market Cap: $233.64M
• Dividend Yield: N/A
• Average Volume (3M): 22.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.76
• Revenue Growth: 5.44%
• EPS Growth: 72.17%
• Country: US
• Employees: 674
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.22
• Shares Outstanding: 9,034,111
• 10 Day Avg. Volume: 13,298
• 30 Day Avg. Volume: 22,645
• PEG Ratio: <0.01
• Price to Book (P/B): 0.09
• Price to Sales (P/S): 0.10
• P/FCF Ratio: -0.52
• Enterprise Value/Market Cap: -0.10
• Enterprise Value/Revenue: -0.04
• Enterprise Value/Gross Profit: -0.06
• Enterprise Value/Ebitda: 0.38
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: $21.00 ▲(7.80% Upside)

Burning Rock Biotech's overall stock score is primarily influenced by its technical analysis, which shows positive momentum. However, significant financial challenges and a negative valuation score due to ongoing losses and lack of dividend yield weigh down the overall score. The absence of earnings call insights and corporate events limits additional context for potential investors.

Positive Factors

Revenue Growth

The revenue growth indicates a positive trend in the company's ability to generate sales, particularly from pharma R&D services, which supports long-term business expansion.

Gross Margin Improvement

Improved gross margins suggest enhanced operational efficiency and profitability, which are crucial for sustaining long-term financial health.

Cost Control Measures

Effective cost management reflects strong operational discipline, which can improve profitability and support sustainable growth.

Negative Factors

Declining Revenue Trend

A declining revenue trend poses a risk to long-term growth and market competitiveness, necessitating strategic adjustments to reverse this pattern.

Negative Cash Flow

Persistent negative cash flow indicates challenges in generating sufficient cash from operations, which could hinder future investments and growth.

Net Losses

Ongoing net losses impact financial stability and investor confidence, requiring strategic initiatives to achieve profitability.

Burning Rock Biotech Business Overview & Revenue Model

Company Description

Burning Rock Biotech (BNR) is a leading precision oncology company based in China that focuses on the development of innovative genomic testing solutions for cancer patients. The company specializes in the research and development of advanced diagnostic products, including next-generation sequencing (NGS) assays that enable personalized treatment strategies. BNR operates primarily in the biotechnology sector, offering services that facilitate early detection and targeted therapies for various forms of cancer, thereby improving patient outcomes.

How the Company Makes Money

Burning Rock Biotech generates revenue through a diverse range of business activities. The primary revenue streams include the sale of its genomic testing products and services to hospitals and medical institutions, which utilize these tests for cancer diagnosis and treatment decisions. Additionally, the company engages in partnerships with pharmaceutical firms for companion diagnostics, which further enhances its revenue through collaborative development and commercialization efforts. Research and development contracts with governmental and private entities also contribute to its earnings, as do potential licensing agreements for its proprietary technologies. Furthermore, as the demand for personalized medicine grows, BNR benefits from increased usage of its testing services, driving growth in its overall revenue.

Burning Rock Biotech Financial Statement Overview

Summary

Burning Rock Biotech faces significant financial challenges with declining revenues and persistent net losses. The balance sheet is relatively stable with low leverage, but negative cash flow from operations is a concern. The company needs to enhance revenue generation and operational efficiency to improve its financial health.

Income Statement

Burning Rock Biotech shows a declining revenue trend with a negative revenue growth rate of -4.03% from 2023 to 2024. Gross profit margin is relatively stable but the net profit margin remains deeply negative due to substantial net losses. The EBIT and EBITDA margins are also negative, indicating ongoing operational challenges and inefficiencies. The company needs to focus on revenue stabilization and cost control to improve its income statement.

Balance Sheet

The company's balance sheet shows a relatively healthy equity ratio with stockholders' equity forming a significant part of total assets. The debt-to-equity ratio is low at 0.09, indicating low leverage which is a positive sign for financial stability. However, the return on equity is negative due to consistent net losses, which impacts the overall attractiveness of the balance sheet.

Cash Flow

Burning Rock Biotech's cash flow statement reflects negative operating cash flows, though there is an improvement from the previous year. Free cash flow remains negative, reflecting ongoing cash burn. The operating cash flow to net income ratio is challenging due to both figures being negative, and the company needs to improve cash generation from operations to sustain long-term growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	539.27M	515.82M	537.43M	563.24M	507.86M	429.90M
Gross Profit	393.77M	362.40M	363.23M	380.04M	364.15M	313.92M
EBITDA	-63.91M	-270.23M	-517.90M	-856.31M	-746.50M	-373.26M
Net Income	-121.25M	-346.63M	-653.69M	-971.23M	-796.70M	-407.24M
Balance Sheet
Total Assets	812.17M	885.30M	1.04B	1.59B	2.28B	2.66B
Cash, Cash Equivalents and Short-Term Investments	463.99M	519.85M	615.10M	905.45M	1.50B	2.26B
Total Debt	33.18M	52.32M	12.32M	50.79M	86.69M	46.88M
Total Liabilities	262.59M	304.48M	271.59M	429.13M	433.28M	242.02M
Stockholders Equity	549.58M	580.83M	768.41M	1.16B	1.85B	2.42B
Cash Flow
Free Cash Flow	-37.84M	-98.24M	-265.17M	-518.84M	-691.33M	-153.08M
Operating Cash Flow	-32.42M	-92.26M	-255.78M	-456.81M	-477.89M	-73.54M
Investing Cash Flow	-4.88M	-4.41M	-9.30M	-7.46M	81.70M	-109.31M
Financing Cash Flow	1.93M	-72.00K	-48.83M	-86.24M	-52.90M	2.17B

Burning Rock Biotech Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 19.48
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNR, the sentiment is Positive. The current price of 19.48 is above the 20-day moving average (MA) of 19.32, above the 50-day MA of 14.75, and above the 200-day MA of 7.72, indicating a bullish trend. The MACD of 1.62 indicates Negative momentum. The RSI at 66.57 is Neutral, neither overbought nor oversold. The STOCH value of 90.53 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BNR.

Burning Rock Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BNR	57 Neutral	$233.64M	-14.55	-19.87%	―	5.44%	72.17%
SERA	52 Neutral	$137.01M	-4.68	-47.69%	―	1.06%	22.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BDSX	51 Neutral	$53.22M	-1.27	-302.55%	―	22.29%	31.93%
VNRX	42 Neutral	$31.44M	-1.17	―	―	14.48%	36.83%
TRIB	40 Underperform	$16.25M	-0.31	―	―	-4.35%	-6.31%
BNGO	40 Underperform	$16.28M	-0.10	-78.22%	―	-13.84%	88.80%

Burning Rock Biotech Corporate Events

Burning Rock Biotech Schedules 2025 AGM for December 23

Burning Rock Biotech Limited announced that its 2025 Annual General Meeting (AGM) will be held on December 23, 2025, in Shanghai. The AGM will address proposals such as the ratification of Ernst & Young Hua Ming LLP as auditors, the re-election of directors Feng Deng and Licen Lisa Xu, and authorizing directors to implement necessary actions. The board supports these proposals and encourages shareholders to vote in favor. The company has also filed its annual report for the year ended December 31, 2024, with the SEC.

Burning Rock Biotech Announces Q3 2025 Financial Results with Revenue Growth

Burning Rock Biotech reported its financial results for the third quarter of 2025, highlighting a 2.3% increase in total revenues compared to the same period in 2024. The company experienced a significant increase in revenue from pharma research and development services, while revenues from in-hospital and central laboratory businesses decreased. The company’s gross profit improved by 7.6%, with a notable increase in gross margin due to high-margin companion diagnostic projects. Operating expenses decreased by 11.9%, driven by cost control measures and headcount reduction. Despite a net loss of RMB16.8 million, this was a substantial improvement from the previous year’s loss.